These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37360582)

  • 21. Slack Resources, Corporate Performance, and COVID-19 Pandemic: Evidence from China.
    Jin L; Choi JH; Kim S; Cho K
    Int J Environ Res Public Health; 2022 Nov; 19(21):. PubMed ID: 36361231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of business model innovation in the hospitality industry during the COVID-19 crisis.
    Breier M; Kallmuenzer A; Clauss T; Gast J; Kraus S; Tiberius V
    Int J Hosp Manag; 2021 Jan; 92():102723. PubMed ID: 36919038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of the COVID-19 pandemic on dividends.
    Krieger K; Mauck N; Pruitt SW
    Financ Res Lett; 2021 Oct; 42():101910. PubMed ID: 34566530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hospital insolvency and its relationship with income and borrowings from banks: a case-control study with large-scale financial data in Japan.
    Tsuboi S; Mine T; Fukushima T
    SN Bus Econ; 2021; 1(11):150. PubMed ID: 34778822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corporate dividend policy in the time of COVID-19: Evidence from the G-12 countries.
    Ali H
    Financ Res Lett; 2022 May; 46():102493. PubMed ID: 34658678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19, ESG investing, and the resilience of more sustainable stocks: Evidence from European firms.
    Cardillo G; Bendinelli E; Torluccio G
    Bus Strategy Environ; 2022 Jun; ():. PubMed ID: 35942337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does Water Matter? The Impact of Water Vulnerability on Corporate Financial Performance.
    Zheng L; Ye L; Wang M; Wang Y; Zhou H
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 pandemic and debt financing by firms: Unravelling the channels.
    Gopalakrishnan B; Jacob J; Mohapatra S
    Econ Model; 2022 Sep; 114():105929. PubMed ID: 35765417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cui bono? Large-scale evidence on the impact of COVID-19 policy measures on listed firms.
    Haimann M; Kaserer C; Ljubicic K
    Q Rev Econ Finance; 2023 Jun; 89():228-243. PubMed ID: 37132001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Financial and economic impacts of the COVID-19 pandemic on aquaculture in Türkiye and financial policy recommendations.
    Erol S
    Mar Policy; 2022 Dec; 146():105313. PubMed ID: 36187421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 and corporate tax avoidance: International evidence.
    Athira A; Ramesh VK
    Int Bus Rev; 2023 Aug; 32(4):102143. PubMed ID: 37235071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corporate payout, cash holdings, and the COVID-19 crisis: Evidence from the G-7 countries.
    Ntantamis C; Zhou J
    Financ Res Lett; 2022 Dec; 50():103275. PubMed ID: 36034341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The financial impact of COVID-19: Evidence from an event study of global hospitality firms.
    Clark J; Mauck N; Pruitt SW
    Res Int Bus Finance; 2021 Dec; 58():101452. PubMed ID: 36540337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Covid-19 on corporate solvency and possible policy responses in the EU.
    Mirza N; Rahat B; Naqvi B; Rizvi SKA
    Q Rev Econ Finance; 2023 Feb; 87():181-190. PubMed ID: 32982131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Firm-level short selling and the local COVID-19 pandemic: Evidence from China.
    He J; Ma X; Wei Q
    Econ Model; 2022 Aug; 113():105896. PubMed ID: 35578633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Firms' participation in the Swiss COVID-19 loan programme.
    Fuhrer LM; Ramelet MA; Tenhofen J
    Swiss J Econ Stat; 2021; 157(1):2. PubMed ID: 33968811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 Outbreak and Financial Performance of Chinese Listed Firms: Evidence From Corporate Culture and Corporate Social Responsibility.
    Sun Y; Li Y
    Front Public Health; 2021; 9():710743. PubMed ID: 34604155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Firms' responses to the COVID-19 pandemic.
    Klöckner M; Schmidt CG; Wagner SM; Swink M
    J Bus Res; 2023 Mar; 158():113664. PubMed ID: 36685011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why the COVID-19 Pandemic Could Increase the Corporate Saving Trend in the Long Run.
    Demary M; Hasenclever S; Hüther M
    Inter Econ; 2021; 56(1):40-44. PubMed ID: 33518788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Covid-19 Economic Vulnerability Index: EU Evidence.
    Brzyska J; Szamrej-Baran I
    Procedia Comput Sci; 2021; 192():3551-3559. PubMed ID: 34630751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.